Literature DB >> 1683326

Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease.

K Kusugami1, T Matsuura, G A West, K R Youngman, D Rachmilewitz, C Fiocchi.   

Abstract

Interleukin-2 activity of intestinal lamina propria mononuclear cells is decreased in Crohn's disease and ulcerative colitis patients compared with control patients with noninflammatory bowel disease. Factors that might be responsible for this phenomenon were investigated. Most interleukin-2 activity was produced by helper (CD4+) T cells. These were present in comparable numbers in both inflammatory bowel disease and control cultures, but the frequency of interleukin-2-producing cells was significantly (3-4 times) lower among Crohn's disease and ulcerative colitis than control cells. In agreement with this finding, levels of interleukin-2 messenger RNA were substantially decreased in both forms of inflammatory bowel disease compared with controls. Mucosal CD8+ T cells and plastic-adherent cells were unable to suppress interleukin-2 activity by autologous or allogeneic CD4+ T cells. The rate of interleukin-2 absorption was similar for inflammatory bowel disease and control cells. Induction of interleukin-2 by different stimuli (phorbol ester, phytohemagglutinin, or anti-CD3 monoclonal antibody) before or after incubation under basal conditions ("resting") failed to normalize the capacity to generate interleukin-2 by Crohn's disease and ulcerative colitis cells. Prostanoids (prostaglandin E2 and 6-keto-prostaglandin F1 alpha) were produced in large amounts in cultures of inflammatory bowel disease cells, but inhibition by indomethacin failed to restore interleukin-2 activity to control levels. Finally, supernatants from Crohn's disease and ulcerative colitis cell cultures failed to suppress interleukin-2 production by control CD4+ T cells. Our results show that the low interleukin-2 activity detected in inflammatory bowel disease mucosa is not caused by activated suppressor cells, excessive lymphokine utilization or immune stimulation, a defective response to activation signals, or production of inhibitory substances. Rather, the low interleukin-2 activity appears to be related to a loss of interleukin-2-producing mucosal CD4+ T cells. It is concluded that abnormalities of intestinal CD4+ T-cell function are associated with the immunopathogenesis of Crohn's disease and ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683326     DOI: 10.1016/0016-5085(91)90397-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation.

Authors:  I B Autenrieth; N Bucheler; E Bohn; G Heinze; I Horak
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

2.  Molecular mechanism of interleukin-2-induced mucosal homeostasis.

Authors:  Jayshree Mishra; Christopher M Waters; Narendra Kumar
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-23       Impact factor: 4.249

3.  Phenotypic and functional characterization of T-cell lines generated from colonoscopic biopsy specimens in patients with ulcerative colitis.

Authors:  K Kusugami; J Haruta; M Ieda; M Shinoda; T Ando; A Kuroiwa; K Ina; H Iokawa; A Ishihara; S Sarai
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

Review 4.  Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy?

Authors:  M J Weldon; J D Maxwell
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

5.  Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis.

Authors:  S Melgar; M M-W Yeung; A Bas; G Forsberg; O Suhr; A Oberg; S Hammarstrom; A Danielsson; M-L Hammarstrom
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

6.  Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies.

Authors:  E C Ebert; A Panja; K M Das; R Praveen; X Geng; C Rezac; M Bajpai
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

7.  Adequacy of mucosal biopsies for evaluation of intestinal cytokine-specific mRNA. Comparative study of RT-PCR in biopsies and isolated cells from normal and inflamed intestine.

Authors:  K Fukushima; G West; C Fiocchi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

8.  Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease.

Authors:  F Autschbach; G Schürmann; L Qiao; H Merz; R Wallich; S C Meuer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa.

Authors:  E Breese; C P Braegger; C J Corrigan; J A Walker-Smith; T T MacDonald
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

10.  T cell receptor repertoire and mitotic responses of lamina propria T lymphocytes in inflammatory bowel disease.

Authors:  L Qiao; M Golling; F Autschbach; G Schürmann; S C Meuer
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.